MAPT and neurodegenerative disease: While clinical biomarkers have yet to be discovered for other major neurodegenerative diseases, such as PD and FTLD, even in the example of AD, where tau and beta amyloid clinical biomarkers of disease state have been validated, the utility in predicting clinical outcomes is yet to be demonstrated.